Fred Alger Management LLC purchased a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,761 shares of the company's stock, valued at approximately $1,572,000. Fred Alger Management LLC owned about 0.17% of CeriBell at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. FMR LLC bought a new position in shares of CeriBell in the 4th quarter valued at about $128,120,000. ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in shares of CeriBell in the 4th quarter valued at approximately $28,160,000. RA Capital Management L.P. acquired a new position in shares of CeriBell in the 4th quarter valued at approximately $21,340,000. Vanguard Group Inc. acquired a new position in CeriBell during the 4th quarter worth approximately $18,015,000. Finally, Board of Trustees of The Leland Stanford Junior University acquired a new position in CeriBell during the 4th quarter worth approximately $16,143,000.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on CBLL shares. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.50.
View Our Latest Stock Analysis on CBLL
Insider Buying and Selling at CeriBell
In other CeriBell news, CEO Xingjuan Chao sold 15,628 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the completion of the sale, the chief executive officer now directly owns 727,151 shares of the company's stock, valued at $10,987,251.61. This trade represents a 2.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 24,700 shares of company stock worth $372,434.
CeriBell Stock Performance
Shares of CBLL traded up $0.38 during mid-day trading on Friday, reaching $17.97. The company's stock had a trading volume of 198,634 shares, compared to its average volume of 275,009. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The stock's fifty day moving average price is $17.61.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. As a group, equities research analysts predict that CeriBell will post -2.46 earnings per share for the current year.
CeriBell Company Profile
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
